Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.93 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.93 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.93 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | SRC | P12931 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.93 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.93 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.86 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.86 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.86 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.86 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.82 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.79 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.79 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.79 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.79 |
| ▸ | LDHA | P00338 | 1/20 | 0.79 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18089718 | 1.00 | P2RY1 (0.93) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL30066823 | 1.00 | P2RY1 (0.93) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Atpgammas SCHEMBL18089704 | 1.00 | P2RY1 (0.93) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Atpgammas SCHEMBL14942243 | 1.00 | P2RY1 (0.93) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Atpgammas SCHEMBL77440 | 1.00 | P2RY1 (0.93) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Atpgammas SCHEMBL29381816 | 1.00 | P2RY1 (0.93) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL4357990 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Diadenosine Tetraphosphate SCHEMBL4069414 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL21067711 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Diadenosine Tetraphosphate SCHEMBL849869 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007020018-A1 | USE OF PURINERGIC AND PYRIMIDINERGIC RECEPTOR AGONISTS FOR DENDRITIC CELLS BASED IMMUNOTHERAPIES | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2007-02-22 | — | — | WO | claimed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4197533-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Guerin, Patrick (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20170035793-A1 | Use of P2X Purinergic Receptor Agonists to Enhance Insulin Secretion In Pancreatic Beta Cells | BIOCRINE AB (SE) | 2017-02-09 | — | — | US | disclosed |
| CN-102946887-B | P2X purinergic receptor agonists is the application in insulin secretion in strengthening pancreatic beta cell | 迈阿密大学 | 2016-06-29 | — | — | CN | disclosed |
| US-20130053338-A1 | Use of P2X Purinergic Receptor Agonists to Enhance Insulin Secretion in Pancreatic Beta Cells | BIOCRINE AB (SE) | 2013-02-28 | — | — | US | disclosed |
| US-20100256086-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | BAR-ILAN UNIVETRSITY (IL) | 2010-10-07 | — | — | US | disclosed |
| EP-2231688-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | Bar-Ilan University (IL) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009066298-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2009-05-28 | — | — | WO | disclosed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | disclosed |
| EP-1421377-A2 | THE NATURAL LIGAND FOR ORPHAN G PROTEIN COUPLED RECEPTOR GPR86 AND METHODS OF USE | Euroscreen S.A. (BE) | 2004-05-26 | — | — | EP | disclosed |
| US-20040005629-A1 | Natural ligand of orphan G protein coupled receptor GPR86 and methods of use | EUROSCREEN, S.A. (BE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003028712-A2 | PURINERGIC AND PYRIMIDINERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF ACTIVATED CD4+ T LYMPHOCYTE-MEDIATED IMMUNE DISEASES | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2003-04-10 | — | — | WO | disclosed |
| US-20030050235-A1 | Natural ligand for orphan G protein coupled receptor GPR86 and methods of use | OGEDA SA (BE) | 2003-03-13 | — | — | US | disclosed |
| WO-2003014731-A2 | THE NATURAL LIGAND FOR ORPHAN G PROTEIN COUPLED RECEPTOR GPR86 AND METHODS OF USE | EUROSCREEN S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
| US-5958696-A | Quantitative solid phase helicase assay | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5817641-A | Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives | THOMAS JEFFERSON UNIVERSITY (US) | 1998-10-06 | — | — | US | disclosed |
| US-4728730-A | Synthesis of nucleoside thiophosphoanhydrides | WISCONSIN ALUMINI RESEARCH FOUNDATION (US) | 1988-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053612-A1 | Nucleotide regulation of immune responses | NT5C2, ENTPD5, ENTPD1 | P2RY1 7/4885P2RY2 18/4885P2RX1 15/4885 |
| US-20100256086-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | P2RY2, P2RY1, CCR2 | P2RY1 2/4885P2RY2 1/4885P2RX1 13/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | P2RY1 5/4885P2RY2 7/4885P2RX1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.